The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal carcinoma patients

BACKGROUND: Although immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of nasopharyngeal carcinoma (NPC), it is still the second- or third-line treatment after the failure of radiotherapy or chemotherapy. In this study, we aimed to investigate the impact of concurrent chemor...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Guoxian, Li, Xiaoyu, Yang, Lin, Zhao, Jing, Lu, Xiang, Wang, Heng, Song, Jia, Mei, Qi, Hu, Guangyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667149/
https://www.ncbi.nlm.nih.gov/pubmed/34988159
http://dx.doi.org/10.21037/atm-21-5175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667149/
https://www.ncbi.nlm.nih.gov/pubmed/34988159
http://dx.doi.org/10.21037/atm-21-5175

Ejemplares similares